# Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)

> **NCT00092430** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1200 (—)

## Conditions studied

- Measles
- Mumps
- Rubella
- Varicella

## Interventions

- **BIOLOGICAL:** V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks

## Key facts

- **NCT ID:** NCT00092430
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09-26
- **Primary completion:** 2003-06-09
- **Final completion:** 2003-06-09
- **Target enrollment:** 1200 (—)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00092430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00092430, "Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00092430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*